Peter Ulrichts

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 668 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +4

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

Peter Ulrichts, Antonio Guglietta, Torsten Dreier et al. · Journal of Clinical Investigation · 2018 · 382 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

James F. Howard, Vera Bril, Ted M. Burns et al. · Neurology · 2019 · 288 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

Adrian C. Newland, Blanca Sánchez‐González, László Rejtő et al. · American Journal of Hematology · 2019 · 181 citations · Full text

Medicine, Hematology, Pharmacology +17

Mapping of the Leptin Binding Sites and Design of a Leptin Antagonist

Frank Peelman, Katrien Van Beneden, Lennart Zabeau et al. · Journal of Biological Chemistry · 2004 · 142 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17